CorMedix (NASDAQ:CRMD) Posts Earnings Results, Misses Estimates By $0.70 EPS

CorMedix (NASDAQ:CRMD) released its quarterly earnings results on Thursday. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.70), FiscalAI reports. The company had revenue of $128.62 million during the quarter, compared to analysts’ expectations of $127.02 million. CorMedix had a return on equity of 51.77% and a net margin of 75.83%.The company’s revenue was up 312.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.22 EPS.

Here are the key takeaways from CorMedix’s conference call:

• Acquisition and synergies: CorMedix closed the Melinta acquisition in Q3 2025 and says it achieved its targeted $35 million of synergies in Q4 while DefenCath reached peak sales of just under $260 million.
• Guidance affirmed: The company reaffirmed 2026 DefenCath guidance of $150–170M, 2027 DefenCath guidance of $100–125M, and full-year 2026 revenue and Adjusted EBITDA guidance of $300–320M and $100–125M, respectively.
• TDAPA transition risk: On July 1, 2026 TDAPA reimbursement shifts to a bundled add-on which management expects will cause price erosion in Q3–Q4 2026; negotiations with customers are ongoing and 2027 reimbursement may improve but near-term revenue concentration is expected to be front‑loaded into H1 2026.
• Pipeline catalyst — REZZAYO: Top-line data from the phase 3 ReSPECT study for REZZAYO prophylaxis are expected in Q2 2026, and management estimates the REZZAYO opportunity at roughly $2.5 billion across indications.
• Strong financial position: Q4 net revenue was $128.6M (DefenCath $91.2M, Melinta $37.4M), full-year pro forma revenue was $401.3M, cash and short-term investments totaled $148.5M, and the company has an active share repurchase program.

CorMedix Stock Up 1.1%

Shares of CorMedix stock traded up $0.07 during trading on Friday, reaching $6.37. The company’s stock had a trading volume of 500,949 shares, compared to its average volume of 2,800,133. CorMedix has a 1-year low of $5.60 and a 1-year high of $17.43. The company has a 50-day simple moving average of $8.17 and a two-hundred day simple moving average of $10.40. The company has a quick ratio of 1.73, a current ratio of 1.94 and a debt-to-equity ratio of 0.39. The company has a market cap of $501.89 million, a price-to-earnings ratio of 3.09 and a beta of 1.31.

Insider Transactions at CorMedix

In other news, CEO Joseph Todisco sold 30,000 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $12.00, for a total value of $360,000.00. Following the completion of the transaction, the chief executive officer directly owned 509,496 shares in the company, valued at $6,113,952. This trade represents a 5.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Alan W. Dunton sold 20,000 shares of CorMedix stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $13.00, for a total transaction of $260,000.00. Following the sale, the director owned 40,250 shares of the company’s stock, valued at approximately $523,250. The trade was a 33.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 90,000 shares of company stock worth $1,095,200. Insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On CorMedix

Large investors have recently made changes to their positions in the company. Deerfield Management Company L.P. purchased a new position in CorMedix in the 3rd quarter valued at about $38,656,000. Marshall Wace LLP increased its holdings in shares of CorMedix by 34.6% during the 3rd quarter. Marshall Wace LLP now owns 3,473,494 shares of the company’s stock worth $40,397,000 after buying an additional 893,518 shares during the last quarter. UBS Group AG raised its position in CorMedix by 295.3% in the third quarter. UBS Group AG now owns 1,090,908 shares of the company’s stock valued at $12,687,000 after purchasing an additional 814,964 shares during the period. Jump Financial LLC purchased a new stake in CorMedix in the 3rd quarter valued at about $9,003,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of CorMedix by 259.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 828,781 shares of the company’s stock worth $9,639,000 after acquiring an additional 597,971 shares during the last quarter. 34.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CRMD has been the topic of a number of research analyst reports. Needham & Company LLC dropped their target price on shares of CorMedix from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday. Royal Bank Of Canada set a $13.00 price objective on CorMedix and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Zacks Research lowered CorMedix from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of CorMedix in a report on Wednesday, January 21st. Finally, D. Boral Capital reissued a “buy” rating and set a $14.00 price target on shares of CorMedix in a research report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $15.71.

CorMedix announced that its Board of Directors has approved a stock repurchase plan on Monday, February 2nd that allows the company to buyback $75.00 million in shares. This buyback authorization allows the company to buy up to 12.3% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Trending Headlines about CorMedix

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Needham cut its price target to $14 but kept a “buy” rating, signaling continued analyst conviction and implying material upside from current levels. Article Title
• Positive Sentiment: Analysts and coverage note that a planned buyback plus advancing REZZAYO clinical/commercial data could reduce float and create meaningful upside if upcoming results meet expectations. CorMedix Buyback And REZZAYO Data Shape Valuation And Risk Profile
• Positive Sentiment: Company reported strong Q4 net revenue ($128.6M) and pro forma full‑year 2025 net revenue of $401.3M, and provided a business update in its earnings release that investors may view as supportive of longer‑term growth. Press Release
• Neutral Sentiment: FY‑2026 revenue guidance was set to $300M–$320M versus a consensus near $309.5M — a range that brackets estimates and thus tempers clarity on near‑term upside, leaving room for interpretation. (Company guidance)
• Neutral Sentiment: Short‑interest reports in the news appear inconsistent or inconclusive (reported as 0 shares/NaN changes), so there’s no clear short‑squeeze signal driving moves.
• Negative Sentiment: EPS missed consensus materially (reported EPS below estimates), which is the primary driver of the stock weakness; coverage and transcripts note the earnings miss despite strong revenue growth. CRMD Lags Q4 Earnings Estimates
• Negative Sentiment: Market reaction: multiple outlets report the stock fell after the earnings miss and hit lows not seen in months — short‑term selling pressure reflects disappointment on EPS and uncertainty on near‑term catalysts. CorMedix stock falls after earnings miss

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.